Neurolupus is associated with anti-ribosomal P protein antibodies: An inception cohort study

Briani, Chiara; Lucchetta, Marta; Ghirardello, Anna; Toffanin, Elisabetta; Zampieri, Sandra; Ruggero, Susanna; Scarlato, Marina; Quattrini, Angelo; Bassi, Nicola; Ermani, M.; Battistin, Leontino; Doria, Andrea

doi:10.1016/j.jaut.2008.12.002

Cited by 106 publications

(84 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In keeping with most previous studies, we found a significant association between anti-Rib-R reactivity and the age of the patients [30]. In our study, disease activity score, evaluated by the SLEDAI-2K score, is slightly higher in anti-C22 aab-positive vs. anti-C22-negative patients.…”

Section: Association With Age and Clinical Parameterssupporting

confidence: 92%

Multi-center evaluation of autoantibodies to the major ribosomal P C22 epitope

et al. 2010

View full text Add to dashboard Cite

Anti-ribosomal P (Rib-P) autoantibodies have been demonstrated to be a specific diagnostic marker for systemic lupus erythematosus (SLE). The aim of this study was to evaluate the prevalence of anti-Rib-P (C22) antibodies in patients with SLE drawn from international, multi-center clinics. Sera collected from patients with SLE (n = 333) and various controls (n = 397) in four centers were tested for anti-C22 autoantibodies by ELISA (Dr. Fooke Laboratorien). SLE activity index 2000 (SLEDAI-2K) was assessed for each patient in two centers. Autoantibody profiles were generated for the SLE samples from Canada using two profile assays. Using the manufacturer`s cut-off value, the prevalence of anti-C22 autoantibodies in patients with SLE between the participating centers varied from 18.2 to 29.0%. In the control sera, the prevalence of anti-C22 autoantibodies was low and the titer in the individual control groups varied significantly. In patients with connective tissue disease other than SLE and in patients with infections disease, the anti-C22 reactivity was significantly higher than in healthy controls (P < 0.0001). Overall sensitivity/specificity was 23.1/99.0%, respectively. Anti-Rib-P reactivity was significantly higher in young (mean age 33.9 vs. 45.3 years) SLE patients (P < 0.0001) and was associated with decreased C3 (P = 0.0335) and C4 levels (P = 0.0129). Moderate association between anti-C22 reactivity and SLEDAI-2K was observed in one cohort (P = 0.02). Anti-C22 autoantibodies are frequently and specifically found in patients with SLE. Although an association between anti-C22 reactivity and SLEDAI score was observed in one center, measurement of anti-C22 autoantibodies is likely not appropriate for measuring global disease activity.

show abstract

Section: Association With Age and Clinical Parameterssupporting

confidence: 92%

Multi-center evaluation of autoantibodies to the major ribosomal P C22 epitope

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Anti-Rib-P antibodies were thought to be one of the biomarkers for NPSLE [12][13][14][15][16][17][18]. Anti-Rib-P antibodies and their associations with neuropsychiatric manifestations were also reported by Hassan et al [15] among Pakistani SLE patients.…”

Section: Discussionmentioning

confidence: 93%

Neuropsychiatric manifestations and associated autoantibodies in systemic lupus erythematosus patients from Western India

et al. 2014

View full text Add to dashboard Cite

Systemic lupus erythematosus with neuropsychiatric involvement (NPSLE) can be diagnosed clinically, but there is no definite serological biomarker established. The objectives of this study were to evaluate the neuropsychiatric involvement in systemic lupus erythematosus (SLE) patients and to detect the autoantibodies associated with them. Sixty NPSLE patients along with sixty SLE patients without neuropsychiatric involvement from Maharashtra, India, were included. All patients were clinically diagnosed using the American College of Rheumatology criteria. Disease activity was assessed using the systemic lupus erythematosus disease activity index. Antinuclear antibodies (ANA), anti-dsDNA, anti-neuronal antibodies were detected by indirect immunofluorescence test. Anti-ribosomal antibodies (anti-Rib-P) were tested by ELISA. NPSLE was diagnosed in age group ranging between 10 and 20 years compared with SLE patients without neuropsychiatric involvement (21-30 years). The most frequent symptoms were psychosis (75%), followed by seizures (58%), lupus headache (40%), cognitive dysfunction (36%), mood disorder (30%), cerebrovascular disease (20%), and anxiety (18%). ANA were present in all. The prevalence of anti-Rib-P was 26.6% in NPSLE and 16.6% in SLE patients without neuropsychiatric involvement. Anti-neuronal antibodies were found in 56.7% in NPSLE and 43.4% in SLE patients without neuropsychiatric involvement. Anti-neuronal antibodies were found to be highest in the patients of psychosis (66.6%) followed by central nerve system disease (63.63 %) and seizures (56.25%). There was an early onset of neuropsychiatric involvement. Anti-Rib-P antibodies as well as anti-neuronal antibodies did not show statistically significant correlation with neuropsychiatric manifestations in NPSLE patients.

show abstract

“…These results attest to the reliability of the immunoproteomic approach used in this study for identifying autoantigens in SLE. Phosphorylated ribosomal (P ribosomal) proteins are three ubiquitous, highly conserved acidic phosphoproteins (P0, P1, and P2) that play roles in protein synthesis (35). The ribosomal protein P0 localizes to the membrane surface of neuronal, hepatic, and endothelial cells in an immunologically accessible way.…”

Section: Discussionmentioning

confidence: 99%

Identification of Three New Autoantibodies Associated with Systemic Lupus Erythematosus Using Two Proteomic Approaches

Katsumata

Kawaguchi

Baba

et al. 2011

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

Our objective was to identify new serum autoantibodies associated with systemic lupus erythematosus (SLE), focusing on those found in patients with central nervous system (CNS) syndromes. Autoantigens in human brain proteins were screened by multiple proteomic analyses: two-dimensional polyacrylamide gel electrophoresis/Western blots followed by matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry analysis and immunoprecipitation followed by liquid chromatographytandem mass spectrometry shotgun analysis. The presence of serum IgG autoantibodies against 11 selected recombinant antigens was assessed by Western blot and enzymelinked immunosorbent assay (ELISA) in the sera of 106 SLE patients and 100 normal healthy controls. The O.D. values in sera from SLE patients were significantly higher than those of controls for the antigens crystallin ␣B (p ‫؍‬ 0.0002), esterase D (p ‫؍‬ 0.0002), APEX nuclease 1 (p < 0.0001), ribosomal protein P0 (p < 0.0001), and PA28␥ (p ‫؍‬ 0.0005); the first three are newly reported. The anti-esterase D antibody levels were significantly higher in the CNS group than in the non-CNS group (p ‫؍‬ 0.016). Moreover, when the SLE patients were categorized using CNS manifestations indicating neurologic or psychiatric disorders, the anti-APEX nuclease 1 antibody levels were significantly elevated in SLE patients with psychiatric disorders (p ‫؍‬ 0.037). In conclusion, the association of SLE with several new and previously reported autoantibodies has been demonstrated. Statistically significant associations between anti-esterase D antibodies and CNS syndromes as well as between anti-APEX nuclease 1 antibodies and psychiatric disorders in SLE were also demonstrated. The combined immunoproteomic approaches used in this study are reliable and effective methods for identifying SLE autoantigens. Molecular &

show abstract

Neurolupus is associated with anti-ribosomal P protein antibodies: An inception cohort study

Cited by 106 publications

References 34 publications

Multi-center evaluation of autoantibodies to the major ribosomal P C22 epitope

Multi-center evaluation of autoantibodies to the major ribosomal P C22 epitope

Neuropsychiatric manifestations and associated autoantibodies in systemic lupus erythematosus patients from Western India

Identification of Three New Autoantibodies Associated with Systemic Lupus Erythematosus Using Two Proteomic Approaches

Contact Info

Product

Resources

About